RegeneRx Biopharmaceuticals Inc (OTCQB: RGRX), a clinical-stage drug development company, is likely to complete its phase three clinical trial of RGN-259 for dry eye syndrome (ARISE-3) in November 2020, it was reported on Wednesday.
The company had enrolled 700 patients in the trial. The estimated study completion date and collection of data for the primary and secondary result measures will be in December, 2020.
J J Finkelstein, president and chief executive, said, 'We are pleased ARISE-3 is near completion, despite the challenges posed by the COVID-19 pandemic. This phase 3 trial is a critical milestone in the development of RGN-259 for dry eye syndrome and crucial to our future success. We look forward to announcing top line results as soon as practicable upon completion of the trial.'
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval